68-5

92/120

542demyelinating diseases of the central nervous system. Sci Rep, 2020; 10: 2679. doi: 10.1038/s41598-020-59760-3. PubMed PMID: 32042055; PubMed Central PMCID: PMC7010775. 11) Daida K, Funayama M, Li Y, Yoshino H, Hayashida A, Ikeda A, Ogaki K, Nishioka K, Hattori N: Identification of Disease-Associ‑ated Variants by Targeted Gene Panel Rese‑quencing in Parkinson’s Disease. Front Neurol, 2020; 11:576465. doi: 10.3389/fneur.2020.576465. 12) Daida K, Nishioka K, Li Y, Yoshino H, Shimada T, Dougu N, Nakatsuji Y, Ohara S, Hashimoto T, Okiyama R, Yokochi F, Suzuki C, Tomi‑yama M, Kimura K, Ueda N, Tanaka F, Yamada H, Fujioka S, Tsuboi Y, Uozumi T, Takei T, Matsuzaki S, Shibasaki M, Kashi‑hara K, Kurisaki R, Yamashita T, Fujita N, Hirata Y, Ii Y, Wada C, Eura N, Sugie K, Higuchi Y, Kojima F, Imai H, Noda K, Shimo Y, Funayama M, Hattori N: PLA2G6 variants associated with the number of affected alleles in Parkinson’s disease in Japan. Neurobiol Aging, 2021; 97: 147.e1-147.e9. doi:10.1016/j.neurobiolaging.2020.07.004. 13) Daida K, Nishioka K, Takanashi M, Kobayashi M, Yoshikawa K, Kusunoki S, Yokoyama K, Hattori N: New-onset Refractory Status Epilep‑ticus Involving the Limbic System, Spinal Cord, and Peripheral Nerves. Intern Med, 2020; 59: 267-270. doi: 10.2169/internalmedi‑cine.3510-19. 14) Daida K, Ogaki K, Hayashida A, Ando M, Yokoyama K, Noda K, Kanbayashi T, Hattori N, Okuma Y: Somnolence Preceded the Devel‑opment of a Subthalamic Lesion in Neuromy‑elitis Optica Spectrum Disorder. Intern Med, 2020; 59: 577-579. doi: 10.2169/internalmedi‑cine.2947-19. 15) Fujimoto U, Ogawa A, Osada T, Tanaka M, Suda A, Hattori N, Kamagata K, Aoki S, Konishi S: Network Centrality Reveals Disso‑ciable Brain Activity during Response Inhibi‑tion in Human Right Ventral Part of Inferior Frontal Cortex. Neuroscience, 2020; 433: 163- 173. doi: 10.1016/j.neuroscience.2020.03.010. 16) Fujita S, Hagiwara A, Takei N, Hwang KP, Fukunaga I, Kato S, Andica C, Kamagata K, Yokoyama K, Hattori N, Abe O, Aoki S: Accel‑erated Isotropic Multiparametric Imaging by High Spatial Resolution 3D-QALAS With Compressed Sensing: A Phantom, Volunteer, and Patient Study. Invest Radiol, 2020. doi: 10.1097/RLI.0000000000000744. Epub ahead of print. 17) Goto M, Kamagata K, Saito A, Abe O, Motoi Y, Miyajima M, Nakajima M: Detection of lesions depends on the DARTEL template used in group comparisons with voxel-based morphometry. Acta Radiol, 2020; 61: 236. 18) Hamamichi S, Fukuhara T, Hattori N. Immu‑notoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. Toxins (Basel), 2020; 12: 658. doi: 10.3390/toxins12100658. PMID: 33076544; PMCID: PMC7602748. 19) Hasegawa H, Yatomi K, Mitome-Mishima Y, Miyamoto N, Tanaka R, Oishi H, Arai H, Hattori N, Urabe T: Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes. Neurosci Res, 2020: S0168-0102(20)30481-8. doi: 10.1016/j.neures.2020.09.004. 20) Hattori N, Kitabayashi H, Kanda T, Nomura T, Toyama K, Mori A: A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson’s Disease. Mov Disord, 2020; 35: 1481-1487. doi: 10.1002/mds. 28095. 21) Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H: Ropinirole Patch Versus Placebo, Ropini‑role Extended-Release Tablet in Advanced Parkinson’s Disease. Mov Disord, 2020; 35: 1565-1573. doi:10.1002/mds.28071. 22) Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M; ME2125-3 Study Group: Effi‑cacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkin‑son’s disease: A randomized, double-blind, placebo-controlled, phase II/III study. Parkin‑sonism Relat Disord, 2020; 75: 17-23. doi:10. 1016/j.parkreldis.2020.04.012. 23) Hattori N: Elsevier/NSR Symposium: The 20th Anniversary of Parkin Discovery-To the Past, the Present, and the Future. Neurosci Res, 2020; 159: 1-2. doi: 10.1016/j.neures.2020.11.001. 24) Hayashi N, Atsuta N, Yokoi D, Nakamura R, Nakatochi M, Katsuno M, Izumi Y, Kanai K,